But at $2.70 they had the silver lining of the huge MSA backlog and the hope that they were done with these "unexpected" charges or cost overruns continuing. I'll agree that the stock looks compelling (still hold a portion of my GV shares), but as mentioned previously, they need to eliminate the "recurring" - non-recurring expenses that seem to wipe out most of the profits they generate from the MSA work.
Dalton, "when they have a clean qtr." That's a BIG IF! I've followed their quarterly reports for the last 3 years, and there is always some sort of "non-recurring" expense that comes thru. Until they can show two or three back to back reports of "clean" numbers, there will always be a black cloud overhanging this stock.